Why We Upgraded This Emerging-Market Stock Fund
Skilled investors keep this strategy’s quant process running smoothly.

Key Morningstar Metrics for Causeway Emerging Markets
- : SilverMorningstar Medalist Rating
- : Above AverageProcess Pillar
- : HighPeople Pillar
- : HighParent Pillar
Causeway Emerging Markets CEMIX (including a US mutual fund, separately managed account, and collective investment trust) has an impressive crew that has earned an upgrade to a High People rating and maintains its Above Average Process rating.
People matter to a quantitative strategy as much as they do at a fundamental one. To keep a computer-driven approach humming, its investors must constantly upgrade factor research, which takes time, talent, and expertise. In this strategy’s three-tiered team, the four portfolio managers include two quants who built the strategy in 2007, Arjun Jayaraman and MacDuff Kuhnert, plus seasoned pros Joe Gubler and Ryan Myers. They focus largely on supervising research and assessing whether new factors belong in the model. Senior research analysts Andrew Liu, Tong Lu, Huray Basar, and Marshall Dong design and pitch new factors and hone them until success or failure is clear. Three research analysts work on others’ ideas and do other heavy lifting. Overall, Causeway’s team is well structured, highly experienced, and boasts proven results here and on other strategies such as Causeway International Small Cap CIISX.
This strategy’s systematic process, like many competitors’, rests upon many contributing quantitative factors that add up to assess a stock on its growth, valuation, and momentum factors. And, like systematic rivals, the team works continually to upgrade and refine its factor set. Two key differences give this approach an edge. First, the weightings of the factors here differ from stock to stock to reflect the specific traits that each stock has: Valuation matters more for cheap stocks, while growth factors matter more for companies that are scaling up. Second, the quant team works with Causeway’s fundamental team to develop a macro perspective that drives 25% of the model’s weighting via sector, country, and currency tilts. The end output is a roughly 120-200 stock portfolio with fairly moderate tilts versus the index’s stock, sector, and country exposures.
Causeway Emerging Markets: Performance Highlights
This strategy’s returns since inception are very strong. Its institutional share class’ 6.9% annualized return from its March 2007 inception through September 2026 thumped the typical diversified emerging-markets Morningstar Category peer’s 4.9% gain and significantly exceeded the MSCI Emerging Markets Index’s 5.7% gain.
It’s worth noting that the strategy has had long cycles of outperformance and underperformance. It was strong in almost every calendar year from 2009 through 2014. It then ranked below average in most years from 2015 through 2022. And it’s been roughly top quintile or better every year since, including an 18th percentile standing in 2026 through September. In its stretch of eight subpar years, it’s worth noting that the MSCI Emerging Markets Growth Index topped the MSCI Emerging Markets Value Index in seven of those years, and this strategy usually has a definite value tilt, so the lag was largely a style headwind.
According to Causeway’s attribution analysis, there’s been a definite tilt in the strong outperformance in the first eight months of 2026. Of the 10 most meaningful contributors versus the benchmark, six came from the broad technology area. Moreover, by far the most potent stock pick was SK Hynix, which featured a high active weighting in this strategy and gained more than 170% over the period. It’s worth noting that the second-most significant contributor on an absolute basis, Taiwan Semiconductor Manufacturing, was detrimental on a relative basis because the strategy had been underweight in it for much of the year.
This article was generated with the help of automation and reviewed by Morningstar editors. Learn more about Morningstar’s use of automation.
The author or authors own shares in one or more securities mentioned in this article. Find out about Morningstar’s editorial policies.
